À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå - ¼¼°è ¹× Áö¿ªº° ºÐ¼® : Ç÷§Æû À¯Çüº°, ÀûÀÀÁõ À¯Çüº°, ÀÀ¿ë À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - ºÐ¼®°ú ¿¹Ãø(2025-2035³â)
Voice/Vocal Biomarker Market - A Global and Regional Analysis: Focus on Platform Type, Application, Indication, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
»óǰÄÚµå : 1802931
¸®¼­Ä¡»ç : BIS Research
¹ßÇàÀÏ : 2025³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,857,000
PDF and Excel (1-3 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,495,000
PDF and Excel (Global License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿¶õ °Ç°­»óŸ¦ °¨Áö, ¸ð´ÏÅ͸µ, ¿¹ÃøÇϱâ À§ÇØ Àΰ£ÀÇ ¸ñ¼Ò¸® Ư¡¿¡¼­ À¯·¡ÇÑ »ý¹°ÇÐÀû ¸¶Ä¿¸¦ °³¹ß, »ó¿ëÈ­, ÀÀ¿ëÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â µðÁöÅÐ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀϺηΠÇÇÄ¡, Åæ, Á֯ļö, ÁøÆø, ÁøÆø, ¹ßÈ­¼Óµµ, ¶³¸² µî ÃøÁ¤ °¡´ÉÇÑ ¹ß¼º Ư¡À» °¡Áö°í ÀÖÀ¸¸ç, »ý¸®Àû ¶Ç´Â º´¸®Àû »óÅÂ¿Í »ó°ü°ü°è°¡ ÀÖ¾î ºñħ½ÀÀû Áø´Ü ¹× ¸ð´ÏÅ͸µÀÌ °¡´ÉÇÕ´Ï´Ù. À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡´Â ½Å°æÁúȯ(ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´ µî), Á¤½ÅÁúȯ(¿ì¿ïÁõ, ºÒ¾ÈÁõ µî), È£Èí±âÁúȯ, ½ÉÇ÷°üÁúȯ, ÀÎÁö±â´ÉÀúÇÏ µî Áúº´ÀÇ Ãʱâ ¡Èĸ¦ ÆÄ¾ÇÇϱâ À§ÇØ À½¼º µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í ºÐ¼®ÇÏ´Â ¼ÒÇÁÆ®¿þ¾î Ç÷§Æû, AI, ¸Ó½Å·¯´× ¾Ë°í¸®Áò, Çϵå¿þ¾î Áø´Ü µµ±¸, ÅëÇÕ ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀÌ Æ÷ÇԵ˴ϴÙ. ¹× ±â°èÇнÀ ¾Ë°í¸®Áò, Çϵå¿þ¾î Áö¿ø Áø´Ü µµ±¸, ÅëÇÕ ¿ø°ÝÀÇ·á ¼Ö·ç¼ÇÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, À£´Ï½º, ÀÎÁö ÇÇÆ®´Ï½º, ±¹¹æ, »ê¾÷À§»ý¿¡ ´ëÇÑ ÀÀ¿ëµµ ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ¿ø°ÝÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±âÁ¸ Áø´Ü ¹æ¹ý¿¡ ºñÇØ ºü¸£°í È®Àå °¡´ÉÇÏ¸ç ºñ¿ë È¿À²ÀûÀÎ ½ºÅ©¸®´×À» Á¦°øÇÏ´Â À½¼º ºÐ¼®ÀÇ ´É·Â¿¡ ÈûÀÔ¾î ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
¿¹Ãø ±â°£ 2025-2035³â
2025³â Æò°¡ 12¾ï 4,350¸¸ ´Þ·¯
2035³â ¿¹Ãø 53¾ï 9,770¸¸ ´Þ·¯
CAGR 15.81%

½ÃÀå ¼Ò°³

¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2035³â¿¡´Â 53¾ï 9,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ÁÖ·Î À½¼º ÆÐÅϰú À½¼º ºÐ¼®À» ÅëÇØ ´Ù¾çÇÑ °Ç°­ »óŸ¦ Áø´ÜÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â »õ·Î¿î Çõ½ÅÀû Á¢±Ù ¹æ½ÄÀÔ´Ï´Ù. ÀΰøÁö´É(AI), ¸Ó½Å·¯´×, ÀÚ¿¬¾î ó¸®(NLP)ÀÇ ¹ßÀüÀ¸·Î º¸´Ù Á¤È®ÇÏ°í ºñħ½ÀÀûÀÎ Áø´Ü µµ±¸°¡ °¡´ÉÇØÁö¸é¼­ ÀÌ ºÐ¾ß´Â ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

Sonde Health, Canary Speech, Winterlight¿Í °°Àº À½¼º ¹× ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±â¾÷µéÀº AI ±â¹Ý ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇÏ¿© ½Å°æÁúȯ, Á¤½ÅÁúȯ, ÀÎÁöÀå¾Ö¸¦ °¨ÁöÇϱâ À§ÇØ À½¼º ÆÐÅÏÀ» ºÐ¼®Çϰí ÀÖ½À´Ï´Ù. ÀÌ ¼Ö·ç¼ÇÀº À½Á¤, Åæ, ¸®µë, ¼Óµµ µî ¹ß¼º Ư¡À» Æò°¡ÇÏ°í ¾ËÃ÷ÇÏÀ̸Ӻ´, ÆÄŲ½¼º´, ¿ì¿ïÁõ, ºÒ¾ÈÁõ µî Áúº´ÀÇ Ãʱâ ¡Èĸ¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ÀÎÁöÀå¾Ö ¹× ±âŸ ½Å°æÁúȯÀÇ ¸ð´ÏÅ͸µ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À½¼º ¹× ¹ßÈ­ ÆÐÅÏÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ °¨ÁöÇÒ ¼ö ÀÖ¾î Á¶±â °³ÀÔ ¹× Áúº´ ÁøÇàÀ» º¸´Ù Á¤È®ÇÏ°Ô ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ Ä¡¸Å ¹× ±âŸ ³ëÈ­¿¡ µû¸¥ ÀÎÁö ÁúȯÀÇ °ü¸®¸¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀÇ °¡Àå Å« ÀåÁ¡ Áß Çϳª´Â ºñħ½ÀÀûÀ̶ó´Â Á¡ÀÔ´Ï´Ù. ħ½ÀÀû ½Ã¼úÀ̳ª ´ë±Ô¸ð °Ë»ç°¡ ÇÊ¿äÇÑ ±âÁ¸ Áø´Ü µµ±¸¿Í ´Þ¸®, ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ªÀº À½¼º ±â·Ï(´ëºÎºÐ 30-40ÃÊ)À» ÅëÇØ °Ç°­ ¹®Á¦ÀÇ Á¶±â ¡Èĸ¦ °¨ÁöÇÕ´Ï´Ù. µû¶ó¼­ ƯÈ÷ ¿ø°ÝÁö¿¡¼­ÀÇ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ¿¡ ¸Å¿ì À¯¿ëÇÑ µµ±¸°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ¿ª·®À» °­È­ÇÏ°í ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Sonde Health´Â Ä÷ÄÄ(Qualcomm)°ú Á¦ÈÞÇÏ¿© ÀÚ»çÀÇ À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀ» ¸ð¹ÙÀÏ Ç÷§Æû¿¡ ÅëÇÕÇÏ¿© ÀÏ»óÀûÀÎ ÀåÄ¡·Î °Ç°­ ¸ð´ÏÅ͸µÀ» ÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ¶ÇÇÑ, Winterlight°¡ Cambridge Cognition¿¡ ÀμöµÇ¸é¼­ À½¼º ºÐ¼®À» ÅëÇÑ ÀÎÁö ±â´É Àå¾Ö °¨Áö¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀ» ÇコÄÉ¾î ½Ã½ºÅÛ¿¡ ÅëÇÕÇÏ´Â °ÍÀº ¿ø°ÝÀÇ·á, Á¤½Å°Ç°­, ÀÎÁö °Ç°­ ¸ð´ÏÅ͸µ¿¡ Àû¿ëµÇ¸é¼­ ´õ¿í È®»êµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ÀÓ»ó ȯ°æ, ȯÀÚ °Ç°­ ÁõÁø ÇÁ·Î±×·¥ ¹× ¿¬±¸¿¡¼­ °Ç°­ »óŸ¦ ÃßÀûÇÏ°í ºñ¿ë È¿À²ÀûÀÌ°í ½Ã±âÀûÀýÇÑ ¹æ½ÄÀ¸·Î Áúº´ÀÇ Ãʱâ Áõ»óÀ» °¨ÁöÇϱâ À§ÇØ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Çõ½ÅÀûÀÌ°í ºñħ½ÀÀûÀÎ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ¸¹Àº ÅõÀÚ°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô È®´ëµÉ °ÍÀ̸ç, ±× Àû¿ë ¹üÀ§´Â ½Å°æÇÐÀû ¹× Á¤½Å°Ç°­»Ó¸¸ ¾Æ´Ï¶ó COPD¿Í °°Àº ¸¸¼ºÁúȯ ¹× ½ºÆ®·¹½º ¼öÁØ °¨Áö±îÁö È®´ëµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À½¼º ¹ÙÀÌ¿À¸¶Ä¿ÀÇ À¯¸ÁÇÑ ÀáÀç·Â¿¡µµ ºÒ±¸Çϰí, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× À½¼º µ¥ÀÌÅÍÀÇ À±¸®Àû »ç¿ë¿¡ ´ëÇÑ ¿ì·Á°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº °³ÀÎÀÇ °Ç°­¿¡ ´ëÇÑ ¹Î°¨ÇÑ Á¤º¸¸¦ ¼öÁýÇϱ⠶§¹®¿¡ GDPRÀ̳ª HIPAA¿Í °°Àº ±ÔÁ¦´Â ÇÁ¶óÀ̹ö½Ã º¸È£¸¦ º¸ÀåÇϱâ À§ÇØ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ±â¾÷µéÀº ÀÚ»ç ¼Ö·ç¼ÇÀÌ µ¥ÀÌÅÍ º¸È£¹ýÀ» ÁؼöÇÏ°í »ç¿ëÀÚ µ¥ÀÌÅ͸¦ ¾ÈÀüÇÏ°Ô Ãë±ÞÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

¿ä¾àÇϸé, ¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ´Ù¾çÇÑ °Ç°­ »óŸ¦ Á¶±â¿¡ ¹ß°ßÇϰí Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀûÀ̰í Á¢±Ù °¡´ÉÇϸç È®Àå °¡´ÉÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ´Â ÇコÄÉ¾î ºÐ¾ßÀÇ Çõ½ÅÀû µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó À½¼º ¹ÙÀÌ¿À¸¶Ä¿°¡ ÀÏ»óÀûÀÎ °Ç°­ ¾ÖÇø®ÄÉÀ̼ǿ¡ ÅëÇյǸé ȯÀÚ °á°ú¿Í ÀÇ·á È¿À²¼ºÀÌ Å©°Ô Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ½Å°æÅðÇ༺ Áúȯ(ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´ µî), Á¤½ÅÁúȯ(¿ì¿ïÁõ, ºÒ¾ÈÁõ µî), È£Èí±âÁúȯ(õ½Ä, COPD µî) µî ´Ù¾çÇÑ Áõ»óÀÇ ¸ð´ÏÅ͸µ ¹× Áø´Ü¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ƯÁ¤ ¸ñ¼Ò¸®ÀÇ º¯È­´Â ±âÁ¸¿¡´Â Á¶±â Áø´ÜÀÌ ¾î·Á¿ü´ø ÆÄŲ½¼º´ÀÇ Ãʱ⠽ÅÈ£°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

À½¼º ±â¹Ý ÀÎÁõ: º¸¾È°ú ½Å¿ø È®ÀÎÀÌ °¡Àå Áß¿äÇÑ »ê¾÷¿¡¼­ À½¼º ¹ÙÀÌ¿À¸¶Ä¿´Â À½¼º ¹ÙÀÌ¿À¸ÞÆ®¸¯¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â »ç¶÷ÀÇ ¸ñ¼Ò¸®¸¦ ºÐ¼®ÇÏ¿© µ¶Æ¯ÇÑ Æ¯Â¡(¾ï¾ç, ¾îÁ¶, ¸»Åõ, ¹ßÈ­ ¸®µë µî)À» Á¶»çÇÏ¿© ½Å¿øÀ» ÀÎÁõÇÏ´Â °ÍÀÔ´Ï´Ù. ÀºÇà, Åë½Å, Á¤ºÎ ºÎ¹®¿¡¼­ äÅõǰí ÀÖ½À´Ï´Ù.

¿µÇâ·Â ÇÚÁîÇÁ¸® ÀÎÁõÀ» °¡´ÉÇϰÔÇÔÀ¸·Î½á º¸¾È Çâ»ó, ºÎÁ¤ÇàÀ§ °¨¼Ò, »ç¿ëÀÚ °æÇè Çâ»óÀ» ½ÇÇöÇÕ´Ï´Ù.

°í°´ Áö¿ø, Äݼ¾ÅÍ, °¡»ó ºñ¼­(Alexa, Siri µî)¿¡¼­ À½¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ÁÂÀý°¨, Çູ°¨, ½ºÆ®·¹½º¿Í °°Àº °¨Á¤À» °¨ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. À̸¦ ÅëÇØ ±â¾÷Àº °í°´ÀÇ °¨Á¤ »óÅ¿¡ µû¶ó ´ëÀÀÀ» ´Þ¸®Çϰųª Àü¹® »ó´ã¿ø¿¡°Ô À¯µµÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼ºÐÈ­ 1 : Ç÷§Æû À¯Çüº°

Ŭ¶ó¿ìµå ±â¹ÝÀº ¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ Ç÷§Æû À¯Çüº° ÁÖ¿ä ºÎ¹®À¸·Î 2024³â 79.99%ÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϸç 2025-2035³â ¿¹Ãø ±â°£ µ¿¾È 16.0%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ¼¼°è ½ÃÀå¿¡¼­ Ŭ¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀº À½¼º µ¥ÀÌÅÍÀÇ ¼öÁý, ÀúÀå, ó¸®, ºÐ¼® ¹æ¹ýÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ´ë·®ÀÇ À½¼º µ¥ÀÌÅ͸¦ ó¸®Çϰí Áø´Ü ¹× ¸ð´ÏÅ͸µ ¸ñÀûÀ¸·Î AI ¾Ë°í¸®ÁòÀ» Àû¿ëÇÏ´Â µ¥ ÇÊ¿äÇÑ ÀÎÇÁ¶ó¿Í ¿¬»ê ´É·ÂÀ» Á¦°øÇÕ´Ï´Ù. À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®À» À§ÇÑ Å¬¶ó¿ìµå ±â¹Ý Ç÷§ÆûÀÇ ÃâÇöÀº °Ç°­ Áø´Ü ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ »óȲÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ Ç÷§ÆûÀº AI¿Í ¸Ó½Å·¯´×ÀÇ ÈûÀ» Ȱ¿ëÇÏ¿© À½¼º µ¥ÀÌÅ͸¦ ÇØ¼®ÇÏ°í ¹ß¼º Ư¡À» ½Ç¿ëÀûÀÎ °Ç°­ °ü·Ã ÀλçÀÌÆ®À¸·Î º¯È¯ÇÕ´Ï´Ù. È®Àå °¡´ÉÇÑ Å¬¶ó¿ìµå ÀÎÇÁ¶ó¸¦ Ȱ¿ëÇÏ¿© ½Ç½Ã°£, ¿ø°Ý, ´ë±Ô¸ð ºÐ¼®À» ¿ëÀÌÇÏ°Ô Çϰí, ÀÓ»óÀÇ, ¿¬±¸ÀÚ, µðÁöÅÐ Çコ Çõ½Å°¡µéÀÇ Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù.

¼¼ºÐÈ­ 2 : ÀûÀÀÁõ À¯Çüº°

ÀûÀÀÁõ À¯Çü¿¡ µû¶ó ¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2024³â 33.51%ÀÇ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÑ Á¤½Å°Ç°­ Àå¾Ö ºÐ¾ß°¡ ÁÖµµÇß½À´Ï´Ù. Á¤½Å°Ç°­ Àå¾Ö ÀûÀÀÁõÀÌ À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº Á¤¼­Àû, ½É¸®Àû Çູ¿¡ ´ëÇÑ ºñħ½ÀÀû ½Ç½Ã°£ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. À½¼º ºÐ¼®Àº À½»ö, À½Á¤, ÇÇÄ¡, À½¼º ÆÐÅÏÀ» ºÐ¼®ÇÏ¿© ½ºÆ®·¹½º, ºÒ¾È, ¿ì¿ïÁõ, ±âŸ Á¤½Å°Ç°­ »óŸ¦ °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿¤¸³½Ã½º Çコ(Ellipsis Health)¿Í °°Àº ±â¾÷Àº À½¼º ±â·ÏÀ» ÅëÇØ Á¤½Å°Ç°­À» Æò°¡ÇÏ´Â AI ±â¹Ý Ç÷§ÆûÀ» °³¹ßÇÏ¿© Àû½Ã¿¡ °³ÀÔÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Á¤½Å°Ç°­ °ü¸®¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀº »ç¿ë ÆíÀǼº°ú È®À强À¸·Î ÀÎÇØ ¸¹Àº ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù.

¼¼ºÐÈ­ 3 : ÀÀ¿ë À¯Çüº°

ÀÀ¿ë À¯Çüº°·Î º¸¸é ¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº Áø´ÜÀÌ ÁÖµµÇϰí ÀÖÀ¸¸ç, À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¼º´ë ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ Áø´ÜÀû Ȱ¿ëÀº ºñħ½ÀÀû ±â¼ú, Áúº´ÀÇ Ãʱâ ¡Èĸ¦ °¨ÁöÇÒ ¼ö ÀÖ´Â ´É·Â, ȯÀÚÀÇ °Ç°­À» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â ¿ªÇÒ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. AI, ¸Ó½Å·¯´×, ¿ø°ÝÀÇ·áÀÇ ¹ßÀüÀ¸·Î À½¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ºñ¿ë È¿À²ÀûÀ̰í, È®Àå °¡´ÉÇϸç, Á¢±ÙÇϱ⠽¬¿î ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ƯÈ÷ ½Å°æ°è ¹× È£Èí±âÁúȯ¿¡ ´ëÇÑ Áúº´ °ËÃâÀÇ Á¤È®¼º°ú Àû½Ã¼ºÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó °ËÁõÀÌ ÁøÇàµÇ°í ±â¼úÀÌ ÀÇ·á ½Ã½ºÅÛ¿¡ ÅëÇյʿ¡ µû¶ó À½¼º ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Áø´ÜÀû Ȱ¿ëÀº ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¿¡°Ô Å« ÇýÅÃÀ» °¡Á®´Ù ÁÙ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¼¼ºÐÈ­ 4 : ÃÖÁ¾»ç¿ëÀÚº°

ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é ¼¼°è À½¼º ¹× ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´ÐÀÌ 2024³â 47.02%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. º´¿øÀº À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¸î °¡Áö Àü·«Àû üÁúÀÌ À̸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. Áï, Áø´ÜÇп¡ ´ëÇÑ ÇÙ½ÉÀûÀÎ Âü¿©, ¹æ´ëÇÑ µ¥ÀÌÅÍ ÀúÀå¼Ò, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿¡ ´ëÇÑ ¼÷·Ãµµ, źźÇÑ ÀçÁ¤Àû µÞ¹Þħ, ±×¸®°í ÀÇ·á ³×Æ®¿öÅ© Àüü¿¡¼­ ´©¸®°í ÀÖ´Â ½Å·Ú°¡ ±×°ÍÀÔ´Ï´Ù. ÃÖ÷´Ü ÀÎÇÁ¶ó, ºÐ¾ß °£ ½Ã³ÊÁö È¿°ú, ´ë±Ô¸ð ȯÀÚ Áý´Ü¿¡ ´ëÇÑ Á¢±Ù¼º µîÀ» ÅëÇØ ÀÌµé ±â¾÷Àº ¹ÙÀÌ¿À¸¶Ä¿ Çõ½ÅÀÇ °³¹ß, °ËÁõ ¹× »ó¿ëÈ­¸¦ À§ÇÑ ÃÖÀûÀÇ ÆÄÆ®³Ê·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÌ ÁøÈ­ÇÏ°í ¼º¼÷ÇØÁü¿¡ µû¶ó º´¿øÀº ÀÌ »õ·Î¿î ºÐ¾ßÀÇ ÀÓ»ó µµÀÔ°ú ±â¼ú Çõ½ÅÀ» ÁÖµµÇÏ´Â ÃÖÀü¼±¿¡ °è¼Ó ¼­°Ô µÉ °ÍÀÔ´Ï´Ù.

¼¼ºÐÈ­ 5 : Áö¿ªº°

Àü ¼¼°è À½¼º ¹× ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ƯÈ÷ ¸ð¹ÙÀÏ ÇコÄÉ¾î ±â±â, ¿þ¾î·¯ºí, ¿ø°ÝÀÇ·á ¼­ºñ½º¿¡ AI¿Í MLÀÌ ÅëÇյǸ鼭 °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ±×·¯³ª Àå±âÀûÀÎ Áö¼Ó°¡´É¼º°ú º¸±ÞÀ» º¸ÀåÇϱâ À§Çؼ­´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦¸¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡ Áß Áß±¹Àº ¸¹Àº Àα¸¿Í ºü¸¥ ±â¼ú µµÀÔÀ¸·Î ÀÎÇØ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Àεµ´Â ÀÇ·á ÅõÀÚ Áõ°¡¿Í ¸¸¼ºÁúȯ ºÎ´ã Áõ°¡·Î ÀÎÇØ ±Þ¼ºÀå ½ÃÀå Áß Çϳª·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

Sonde Health, Beyond Verbal, Cogito Corporation, Vocalis Health µî ÁÖ¿ä ±â¾÷µéÀº AI ±â¼úÀ» ÅëÇÕÇÏ¿© À½¼º/¹ß¼º ¼Ö·ç¼ÇÀÇ ±â´ÉÀ» °­È­ÇÏ¿© ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.

¼¼°è À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ

¼ö¿ä - ÃËÁø¿äÀÎ, µµÀü°úÁ¦, ±âȸ

½ÃÀå ¼ö¿ä ÃËÁø¿äÀÎ

À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀº ÇコÄÉ¾î »ê¾÷À» Å©°Ô º¯È­½Ãų °ÍÀÔ´Ï´Ù. ºñħ½ÀÀûÀÌ°í ºñ¿ë È¿À²ÀûÀ̸ç Áö¼ÓÀûÀΠƯ¼ºÀ¸·Î ÀÎÇØ Á¶±â Áø´Ü, Áúº´ ÁøÇà ¸ð´ÏÅ͸µ ¹× ´Ù¾çÇÑ °Ç°­ »óÅ °ü¸®¿¡ ¸Å·ÂÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. À½¼º Ư¼ºÀÇ ÀÚ¿¬½º·¯¿î º¯È­¸¦ Ȱ¿ëÇϸé ÀÓ»óÀÇ´Â Æò¼Ò¿¡´Â ¹ß°ßÇϱ⠾î·Á¿î ȯÀÚÀÇ °Ç°­ »óÅ¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÌ °è¼Ó ¹ßÀüÇÔ¿¡ µû¶ó, ƯÈ÷ AI ¾Ë°í¸®ÁòÀÌ °³¼±µÇ°í ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀÌ À½¼º ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÀÏ»óÀûÀÎ ÀÇ·á ¼­ºñ½º¿¡ ÅëÇÕÇÏ´Â °ÍÀ» °£¼ÒÈ­ÇÔ¿¡ µû¶ó ÀÓ»ó ÇöÀå¿¡¼­ÀÇ Ã¤ÅÃÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀº Áø´Ü ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ Çõ½ÅÀûÀÎ µµ±¸·Î¼­ ´Ù¾çÇÑ ÀÓ»ó ¿µ¿ª¿¡¼­ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

½Å°æÇÐ - ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, ´Ù¹ß¼º °æÈ­Áõ°ú °°Àº ½Å°æÁúȯ¿¡¼­´Â À½¼º ÆÐÅÏÀÌ ¹Ì¹¦ÇÏ°Ô º¯È­ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. À½¼º ºÐ¼®Àº ÀÌ·¯ÇÑ Áúº´ÀÇ Ãʱâ Áõ»ó °¨Áö ¹× ÁøÇà ¸ð´ÏÅ͸µ¿¡ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, ¸ñ¼Ò¸®ÀÇ ¶³¸², À½Á¤, ŸÀ̹ÖÀÇ º¯È­´Â ÆÄŲ½¼º´ÀÇ ¿îµ¿Àå¾Ö³ª Ä¡¸ÅÀÇ ÀÎÁö±â´É ÀúÇϸ¦ ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï´Ù.

Á¤½Å°Ç°­ - ¿ì¿ïÁõ, ºÒ¾È, ½ºÆ®·¹½º¿Í °°Àº Á¤½Å°Ç°­ »óÅ´ ¸»ÀÇ ÆÐÅϰú ¾îÁ¶¸¦ º¯È­½Ãų ¼ö ÀÖ½À´Ï´Ù. AI ¾Ë°í¸®ÁòÀº ÀÌ·¯ÇÑ »óÅÂ¿Í °ü·ÃµÈ ¹ßÈ­ ¼Óµµ°¡ ´À·ÁÁö°Å³ª ¾ï¾çÀÌ ÆòÅºÇØÁö´Â µîÀÇ ¹ß¼º ½ÅÈ£¸¦ °¨ÁöÇÒ ¼ö ÀÖ¾î Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ°ú Á¶±â °³ÀÔÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. À̸¦ ÅëÇØ ´Ü½Ã°£ÀÇ À½¼º »ùÇÃÀ» ÅëÇØ ¿ì¿ïÁõ À§ÇèÀ» ÆÄ¾ÇÇÏ´Â µî ¼öµ¿ÀûÀÌ°í ºñħ½ÀÀûÀÎ ½ºÅ©¸®´×ÀÌ °¡´ÉÇÕ´Ï´Ù.

½ÉÀ庴ÇÐ - ¿¬±¸¿¡ µû¸£¸é ¹ß¼º Ư¼ºÀÌ ½ÉÇ÷°ü °Ç°­ »óŸ¦ ¹Ý¿µÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÄÚ¸·ÈûÀ̳ª È£Èí Àå¾Ö·Î ÀÎÇÑ ¹ß¼º º¯È­´Â ½ÉºÎÀüÀ̳ª °ü»óµ¿¸Æ ÁúȯÀ» ¾Ï½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ±âÁ¸ÀÇ ¹æ¹ý°ú ÇÔ²² ½ÉÀå ÁúȯÀÇ Á¶±â ¹ß°ß ¹× Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀ» À§ÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

È£Èí±âÁúȯ - ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), õ½Ä µî È£Èí±âÁúȯÀº ¸ñ¼Ò¸®¿Í È£ÈíÀ½¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. À½¼º ºÐ¼®Àº õ¸íÀ½, ´ëÈ­ Áß È£Èí°ï¶õ, ±âħ ÆÐÅÏÀ» ÃßÀûÇÒ ¼ö ÀÖÀ¸¸ç, È£Èí±â °Ç°­À» ¸ð´ÏÅ͸µÇÏ°í ¾ÇÈ­¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀûÀÎ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, À½¼º ±â·ÏÀ» ºÐ¼®ÇÏ¿© Æó ±â´É ÀúÇÏÀÇ Â¡Èĸ¦ ½Äº°ÇÔÀ¸·Î½á COPD ȯÀÚ °ü¸®¿¡ µµ¿òÀÌ µÇ´Â À½¼º ¹ÙÀÌ¿À¸¶Ä¿°¡ Å×½ºÆ®µÇ°í ÀÖ½À´Ï´Ù.

±âŸ ÀÓ»óÀû Ȱ¿ë - ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ´ç´¢º´ ÇÕº´Áõ, ÀÎÁöÀå¾Ö, ¿Ü»ó¼º ³ú¼Õ»ó °¨Áö, °íÀ§Çè Á÷¾÷±º¿¡¼­ÀÇ ½ºÆ®·¹½º ¹× ÇÇ·Î ¸ð´ÏÅ͸µ µî¿¡µµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ÀϹÝÀûÀÎ °Ç°­°ü¸® ¹× ¿¹¹æÀÇÇп¡¼­ ¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ÀáÀçÀûÀÎ °Ç°­ ¹®Á¦ÀÇ Á¶±â °æ°í ½ÅÈ£·Î À½¼ºÀ¸·Î ÀÎÇÑ ½ºÆ®·¹½º ¼öÁØÀ» ÃßÀûÇÏ´Â °Ç°­°ü¸® ¾Û°ú °°ÀÌ °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÏ´Â Æí¸®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù.

Âü°í : À§ÀÇ ¸ðµç ¿ä¼Ò´Â º¸°í¼­¿¡¼­ ÀÚ¼¼È÷ Æò°¡µË´Ï´Ù.

½ÃÀåÀÇ °úÁ¦

À½¼º ÆÐÅÏÀÇ º¯µ¿¼º - »ç¶÷ÀÇ ¸ñ¼Ò¸®´Â °¨Á¤ »óÅÂ, °Ç°­ »óÅÂ, ȯ°æ ¼ÒÀ½, ³ªÀÌ, ¼ºº°, ¾ï¾ç µîÀÇ ¿äÀο¡ µû¶ó Å©°Ô ´Þ¶óÁý´Ï´Ù. À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ½Ã½ºÅÛÀº Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ½Äº°À» º¸ÀåÇϱâ À§ÇØ ÀÌ·¯ÇÑ º¯È­¸¦ °í·ÁÇØ¾ß ÇÕ´Ï´Ù.

½ÅÈ£ ǰÁú - ´Ù¸¥ ¸ñ¼Ò¸®³ª ȯ°æ ¼ÒÀ½°ú °°Àº ¹è°æ ¼ÒÀ½Àº À½¼º ½ÅÈ£¸¦ ¿Ö°î½ÃÄÑ ½Ã½ºÅÛÀÌ Á¤È®ÇÑ »ýüÀÎ½Ä µ¥ÀÌÅ͸¦ ¾ò±â ¾î·Æ°Ô ¸¸µì´Ï´Ù. ÀÌ´Â ÅëÁ¦µÈ ȯ°æÀÌ ¾Æ´Ñ ½ÇÁ¦ ȯ°æ¿¡¼­´Â ƯÈ÷ ¾î·Á¿î ¹®Á¦ÀÔ´Ï´Ù.

½Ç½Ã°£ ó¸® - À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ½Ã½ºÅÛÀº ½Ç½Ã°£ ó¸® ´É·ÂÀÌ ÇÊ¿äÇÏÁö¸¸, ÀÌ´Â °è»ê Áý¾àÀûÀÏ ¼ö ÀÖ½À´Ï´Ù. ó¸® Áö¿¬À̳ª ¿À·ù´Â ƯÈ÷ Äݼ¾Åͳª °ø°øÀå¼Ò¿Í °°ÀÌ ±³Åë·®ÀÌ ¸¹Àº ȯ°æ¿¡¼­´Â À߸øµÈ ½Äº° ¹× ÃßÀûÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÏ´Â ´Ù¸¥ °úÁ¦¿¡´Â ´ÙÀ½°ú °°Àº °ÍµéÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿´Â ½Å°æÁúȯ(¿¹: ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´), Á¤½Å°Ç°­ ¹®Á¦(¿¹: ¿ì¿ïÁõ, ºÒ¾ÈÁõ), È£Èí±âÁúȯ(¿¹: ¼ö¸é¹«È£ÈíÁõ, COVID-19) µî ´Ù¾çÇÑ °Ç°­ »óŸ¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´Â ºñħ½ÀÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¼ö´ÜÀ» Á¦°øÇÕ´Ï´Ù. Á¶±â ¹ß°ßÀº ¿¹¹æÀû Ä¡·á¿Í Àû½Ã °³ÀÔÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÀÇ·áºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Vocalis Health´Â AI¸¦ Ȱ¿ëÇÑ À½¼º ºÐ¼®À» ÅëÇØ ¹ßÈ­ ÆÐÅÏÀÇ ¹Ì¹¦ÇÑ º¯È­¸¦ ºÐ¼®ÇÏ¿© ÆÄŲ½¼º´ÀÇ Â¡Èĸ¦ °¨ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ¿ø°ÝÁö³ª À§Ç豺¿¡ ³Î¸® º¸±ÞÇÏ¿© Á¶±â °³ÀÔ°ú °³º°È­µÈ Ä¡·á °èȹÀ» °¡´ÉÇÏ°Ô ÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î Sonde Health¿Í °°Àº ¾ÛÀº À½¼º ¹ÙÀÌ¿À¸¶Ä¿¸¦ Ȱ¿ëÇÏ¿© Á¤¼­Àû °íÅëÀ» ¸ð´ÏÅ͸µÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àû±ØÀûÀÎ °³ÀÔ°ú ¸¸¼ºÀûÀÎ Á¤½Å°Ç°­ »óÅÂÀÇ È¸ÇÇ·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ´ÙÀ½°ú °°Àº °ÍµéÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå µ¿Çâ

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼ú¿¡ AI¿Í MLÀÇ ÅëÇÕÀº ÇコÄɾîÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ ´É·ÂÀÇ Å« µµ¾àÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ºñħ½ÀÀû, ½Ç½Ã°£, °³ÀÎÈ­µÈ ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» Á¦°øÇÒ »Ó¸¸ ¾Æ´Ï¶ó Áúº´ÀÇ Á¶±â ¹ß°ß, ¿ø°Ý ¸ð´ÏÅ͸µ, ¿¹Ãø ºÐ¼®¿¡ »õ·Î¿î ±æÀ» ¿­¾îÁÝ´Ï´Ù. µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿Í ÀÓ»óÀû °ËÁõ¿¡ ´ëÇÑ °úÁ¦´Â ³²¾ÆÀÖÁö¸¸, AI¿Í MLÀÌ À½¼º ¹ÙÀÌ¿À¸¶Ä¿¸¦ ÅëÇØ ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â °¡´É¼ºÀº ¹«±Ã¹«ÁøÇϸç, ´Ù¾çÇÑ °Ç°­ »óÅÂÀÇ Áø´Ü°ú °ü¸®¿¡ Å« ÀÌÁ¡À» °¡Á®´Ù ÁÙ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Ãֽбâ¼ú ¹ßÀü¿¡ ´ëÇÑ ±íÀº ÀλçÀÌÆ®¸¦ Á¦°øÇÏ¿© ±â¾÷ÀÌ Çõ½ÅÀ» ÃËÁøÇÏ°í ½ÃÀå ¿ä±¸¿¡ ¸Â´Â ÃÖ÷´Ü Á¦Ç°À» °³¹ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇϰí ÁÖ¿ä ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Ÿ°ÙÆÃµÈ ¸¶ÄÉÆÃ Àü·«À» ¼ö¸³ÇÏ°í ½ÃÀå ÀÔÁö¸¦ È¿°úÀûÀ¸·Î È®ÀåÇÒ ¼ö ÀÖ´Â Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡´Â öÀúÇÑ °æÀï ȯ°æ ºÐ¼®ÀÌ Æ÷ÇԵǾî ÀÖ¾î À½¼º/¼º´ë ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß¿¡¼­ °æÀï»çÀÇ °­Á¡°ú ¾àÁ¡À» ÀÌÇØÇÏ°í ½ÃÀå¿¡¼­ °æÀï ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ´Â È¿°úÀûÀÎ Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·«Àû À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿¿¡ ƯȭµÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, ½ÂÀÎ ¹× ¾÷°è °¡À̵å¶óÀο¡ ´ëÇÑ ÃֽŠÁ¤º¸¸¦ Á¦°øÇÏ¿© ±â¾÷ÀÌ ±ÔÁ¤ Áؼö¸¦ À¯ÁöÇÏ°í »õ·Î¿î À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

½ÃÀå µ¿Çâ, ÀÚ±Ý Á¶´Þ ÆÐÅÏ, Á¦ÈÞ ±âȸ¸¦ ºÐ¼®ÇÏ¿© ±â¾÷ÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, »ç¾÷ ¼ºÀåÀ» À§ÇÑ ÀáÀçÀûÀÎ M&A ±âȸ¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ ¹× °æÀï»ç ¿ä¾à

±â¾÷ ÇÁ·ÎÆÄÀÏÀº 1Â÷ Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ Àǰ߰ú ±â¾÷ Ä¿¹ö¸®Áö, Á¦Ç° Æ÷Æ®Æú¸®¿À, ½ÃÀå ħÅõµµ ºÐ¼®À» ¹ÙÅÁÀ¸·Î ¼±Á¤µË´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡´Â ÀÇ·á Áø´Ü¿¡¼­ °í°´ ¼­ºñ½º ºÐ¾ßÀÇ °¨¼º Áö´É¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ¿ëµµÀÇ À½¼º µ¥ÀÌÅ͸¦ ºÐ¼® ¹× ÇØ¼®Çϱâ À§ÇØ °í¾ÈµÈ ´Ù¾çÇÑ ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. AI¿Í ¸Ó½Å·¯´×ÀÇ ±â¼ú ¹ßÀüÀ¸·Î À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇÏ¿© ÇコÄɾî, º¸¾È, ÀÚµ¿Â÷, °í°´ ¼­ºñ½º, Åë½Å µîÀÇ »ê¾÷¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀÔ´Ï´Ù. ºñħ½ÀÀû Áø´Ü, ¸ÂÃãÇü ¼­ºñ½º, º¸¾È °­È­¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀº ¸¹Àº ºÐ¾ß¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ÇコÄɾî¿Í À½¼º ÀÎÁõ ºÐ¾ß¿¡¼­ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

À½¼º/¹ß¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡ ÁøÃâÇÑ À¯¸í ±â¾÷µéÀº ´ÙÀ½°ú °°½À´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ À½¼º ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¾÷°è Àü¸Á

Á¦2Àå Ç÷§Æû À¯Çü

Á¦3Àå ÀÀ¿ë À¯Çü

Á¦4Àå ÀûÀÀÁõ

Á¦5Àå ÃÖÁ¾»ç¿ëÀÚ

Á¦6Àå Áö¿ª

Á¦7Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦8Àå Á¶»ç ¹æ¹ý

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

This report can be delivered within 1 working day.

Introduction of Voice/Vocal Biomarker Market

Voice/vocal biomarkers refer to the development, commercialization, and application of biological markers derived from human voice characteristics to detect, monitor, and predict health conditions. Voice/vocal biomarkers are a a part of digital biomarker and has measurable vocal features, such as pitch, tone, frequency, amplitude, speech rate, and tremor, which correlate with physiological or pathological states, enabling non-invasive diagnosis and monitoring. The voice/vocal biomarker market encompasses software platforms, AI and machine learning algorithms, hardware-enabled diagnostic tools, and integrated telehealth solutions that capture and analyze voice data to identify early signs of diseases including neurological disorders (e.g., Parkinson's, Alzheimer's), mental health conditions (e.g., depression, anxiety), respiratory illnesses, cardiovascular disease, and cognitive decline. It also covers applications in wellness, cognitive fitness, defense, and occupational health. Growth in this market has been fueled by technological advancements, the rising need for remote healthcare solutions, and the ability of vocal analysis to offer fast, scalable, and cost-effective screening compared to traditional diagnostic methods.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$1,243.5 Million
2035 Forecast$5,397.7 Million
CAGR15.81%

Market Introduction

The global voice/vocal biomarker market is expected to witness significant expansion, projected to reach 5,397.7 million by 2035.

Voice/vocal biomarkers are an emerging and innovative approach to diagnosing and monitoring various health conditions, primarily through the analysis of voice patterns and speech. The field is rapidly growing, with advancements in artificial intelligence (AI), machine learning, and natural language processing (NLP) enabling more accurate and non-invasive diagnostic tools.

Companies in the voice/vocal biomarker market like Sonde Health, Canary Speech, and Winterlight are leveraging AI-driven algorithms to analyze speech patterns for the detection of neurological, psychiatric, and cognitive disorders. These solutions assess vocal features such as pitch, tone, rhythm, and speed to identify early signs of diseases like Alzheimer's, Parkinson's, depression, and anxiety.

Voice/vocal biomarkers are being increasingly used to monitor cognitive impairment and other neurological conditions. The ability to detect subtle changes in voice and speech patterns allows for earlier interventions and more accurate disease progression tracking. This can significantly enhance the management of conditions like dementia and other age-related cognitive diseases.

One of the major advantages of vocal biomarker technology is its non-invasive nature. Unlike traditional diagnostic tools that require invasive procedures or extensive testing, vocal biomarkers use brief voice recordings (often just 30-40 seconds) to detect early indicators of health issues. This makes it a highly accessible tool for continuous monitoring, especially in remote settings.

Leading companies in the voice/vocal biomarker market space are forming strategic partnerships to enhance their capabilities and expand their market presence. For instance, Sonde Health has teamed up with Qualcomm to integrate its vocal biomarker technology into mobile platforms, enabling health monitoring through everyday devices. Additionally, Winterlight's acquisition by Cambridge Cognition highlights the growing emphasis on cognitive impairment detection via voice analysis.

The integration of vocal biomarker technology into healthcare systems is becoming more widespread, with applications in telemedicine, mental health, and cognitive health monitoring. These tools are increasingly being used in clinical settings, patient wellness programs, and research to track health status and detect early symptoms of diseases in a cost-effective and timely manner.

The voice/vocal biomarker market market is experiencing significant investment, driven by growing demand for innovative and non-invasive diagnostic solutions. Global voice/vocal biomarker market will continue to expand rapidly in the coming years, with applications not just limited to neurological and mental health but extending to chronic conditions like COPD and even detecting stress levels.

Despite the promising potential of vocal biomarkers, there are concerns around data privacy and the ethical use of voice data. As these technologies collect sensitive information about an individual's health, regulations like GDPR and HIPAA are essential to ensure privacy protection. Companies in the sector are focusing on ensuring that their solutions comply with data protection laws and that user data is securely handled.

In summary, global voice/vocal biomarker market positioning themselves as a transformative tool in healthcare, providing a non-invasive, accessible, and scalable solution for early detection and continuous monitoring of a wide array of health conditions. As technology advances, the integration of vocal biomarkers into everyday health applications is expected to significantly improve patient outcomes and healthcare efficiency.

Industrial Impact

Voice/vocal biomarker market are increasingly being used to monitor and diagnose a range of conditions such as neurodegenerative diseases (like Parkinson's or Alzheimer's), mental health disorders (like depression or anxiety), and respiratory diseases (such as asthma and COPD). For example, specific vocal changes can signal early-stage Parkinson's disease, which is traditionally difficult to diagnose early.

Voice-based Authentication: In industries where security and identity verification are paramount, vocal biomarkers are being used for voice biometrics. This involves analyzing a person's voice for unique characteristics (such as accent, tone, and speech rhythm) to authenticate identity. It's being adopted in banking, telecoms, and government sectors.

Impact: Improves security, reduces fraud, enhances user experience by enabling hands-free authentication.

In customer support, call centers, and virtual assistants (like Alexa or Siri), vocal biomarkers help detect emotions such as frustration, happiness, or stress. This allows companies to adapt responses accordingly or route customers to specialized agents based on their emotional state.

Market Segmentation

Segmentation 1: By Platform Type

Cloud-based remains the leading segment by platform type in the global voice/vocal Biomarker market, holding an 79.99% market share in 2024, with a projected CAGR of 16.0% during the forecast period 2025-2035.

Cloud-based platforms in the global voice/vocal biomarker market are transforming how voice data is collected, stored, processed, and analyzed. These platforms provide the infrastructure and computational power needed to process large volumes of speech data and apply AI algorithms for diagnostic and monitoring purposes. The emergence of cloud-based platforms for vocal biomarker analysis is reshaping the landscape of health diagnostics and remote patient monitoring. These platforms harness the power of AI and machine learning to interpret voice data, transforming vocal characteristics into actionable health insights. By leveraging scalable cloud infrastructure, they facilitate real-time, remote, and large-scale analysis, improving accessibility for clinicians, researchers, and digital health innovators.

Segmentation 2: By Indication Type

Based on indication type, the global voice/vocal biomarker market was led by mental health disorder segment, which accounted for a 33.51% market share in 2024. Mental health disorders indication is dominating the voice/ vocal biomarkers market due to the increasing demand for non-invasive, real-time monitoring of emotional and psychological well-being. Voice analysis can detect stress, anxiety, depression, and other mental health conditions by analyzing tone, pitch, and speech patterns. For example, companies like Ellipsis Health have developed AI-powered platforms that assess mental health through voice recordings, enabling timely interventions and improving access to mental health care. This approach is gaining traction due to its ease of use and scalability.

Segmentation 3: By Application Type

Based on application type, the global voice/vocal biomarker market market was led by diagnostics dominating the voice/ vocal biomarkers market. The diagnostics applications in the vocal biomarkers market is driven by the non-invasive nature of the technology, its ability to detect early signs of diseases, and its role in continuous monitoring of patient health. With advancements in AI, machine learning, and remote healthcare, vocal biomarkers provide a cost-effective, scalable, and accessible solution to improve the accuracy and timeliness of disease detection, particularly for neurological and respiratory conditions. As clinical validation progresses and the technology becomes more integrated into healthcare systems, the diagnostic applications of vocal biomarkers are expected to grow even further, offering significant benefits to both patients and healthcare providers.

Segmentation 4: By End User

Based on end user, the global voice/vocal biomarker market market was led by the Hospitals and Clinics segment, which held a 47.02% share in 2024. Hospitals hold a dominant position in the vocal biomarker market, supported by several strategic strengths: their core involvement in diagnostics, expansive data repositories, mastery of regulatory frameworks, and robust financial backing combined with the trust they enjoy across healthcare networks. Their state-of-the-art infrastructure, cross-disciplinary synergies, and access to large patient populations make them optimal partners for the development, validation, and commercialization of vocal biomarker innovations. As these technologies evolve and gain maturity, hospitals are poised to remain at the forefront driving both clinical adoption and innovation in this emerging field.

Segmentation 5: By Region

The global voice/vocal biomarker market market in the Asia-Pacific region is expanding rapidly. The voice/vocal biomarker market in APAC is poised for robust growth, particularly with the integration of AI and ML into mobile health devices, wearables, and telehealth services. However, regulatory frameworks and data privacy concerns need to be addressed to ensure long-term sustainability and widespread adoption.

With respect to countries of the APAC region, China holds the largest market share in the APAC region due to its large population and rapid technological adoption. India is emerging as one of the fastest-growing markets due to rising healthcare investments and an increasing burden of chronic diseases.

Companies such as Sonde Health, Beyond Verbal, Cogito Corporation, and Vocalis Health are leading the market by integrating AI technologies to enhance the capabilities of voice/vocal solutions..

Recent Developments in the Global Voice/Vocal Biomarker Market

Demand -Drivers, Challenges, and Opportunities

Market Demand Drivers:

Vocal biomarker technology represents a game-changer in the healthcare industry. Its non-invasive, cost-effective, and continuous nature makes it an attractive option for early diagnosis, monitoring disease progression, and managing various health conditions. By leveraging the natural variations in voice characteristics, clinicians can gain insights into a patient's health that would otherwise be difficult to detect. As these technologies continue to evolve, we can expect broader adoption across clinical settings, especially as AI algorithms improve and regulatory approvals streamline the integration of voice biomarkers into everyday healthcare. Vocal biomarker technology is being applied across various clinical domains as an innovative tool for diagnosis and monitoring.

Neurology: Neurological disorders such as Parkinson's disease, Alzheimer's, and multiple sclerosis often lead to subtle changes in voice patterns. Voice analysis can help detect early signs of these conditions or monitor their progression. For example, variations in vocal tremor, pitch, or timing may indicate motor impairments in Parkinson's disease or cognitive decline in dementia.

Mental Health: Mental health conditions, including depression, anxiety, and stress, can alter speech patterns and tone. AI algorithms can detect vocal cues, such as slower speech or flat intonation, associated with these conditions, facilitating continuous monitoring and early intervention. This allows for passive, non-intrusive screenings, such as identifying the risk of depression from a brief voice sample.

Cardiology: Research has shown that vocal characteristics can reflect cardiovascular health. Specific vocal patterns may be linked to heart conditions, with changes in speech due to congestion or breathing irregularities potentially signaling heart failure or coronary artery disease. Vocal biomarkers are being explored for early detection and ongoing monitoring of cardiac conditions alongside traditional methods.

Respiratory Disease: Respiratory conditions like chronic obstructive pulmonary disease (COPD) and asthma can affect voice and breathing sounds. Voice analysis can track wheezing, shortness of breath during speech, or coughing patterns, offering a non-invasive method to monitor respiratory health and detect exacerbations early. For example, vocal biomarkers are being tested to help manage COPD patients by analysing voice recordings to identify signs of declining lung function.

Other Clinical Uses: Vocal biomarkers are also being researched for detecting diabetic complications, cognitive impairments, traumatic brain injury, and monitoring stress or fatigue in high-risk professions. In general wellness and preventive care, vocal biomarkers provide a convenient way to monitor health, such as wellness apps tracking voice-derived stress levels as an early warning sign of potential health issues.

Note: All of the above factors will be evaluated in detail in the report.

Market Challenges:

Variability in Voice Patterns: People's voices can vary widely based on factors like emotional state, health conditions, environmental noise, age, gender, and accent. Voice biomarker systems need to account for these variations to ensure accurate and reliable identification.

Signal Quality: Background noise, such as other voices or environmental sounds, can distort the voice signal, making it harder for the system to capture accurate biometric data. This is particularly challenging in real-world environments outside controlled settings.

Real-Time Processing: Voice biomarker systems require real-time processing capabilities, which can be computationally intensive. Delays or errors in processing may lead to incorrect identification or tracking, especially in high-traffic environments like call centers or public spaces.

Some of the other factors challenging the voice/vocal biomarker market growth include:

Note: All of the above factors will be evaluated in detail in the report.

Market Opportunities:

Voice/vocal biomarker provide a non-invasive and cost-effective means for early detection of a range of health conditions, including neurological disorders (e.g., Parkinson's disease, Alzheimer's disease), mental health issues (e.g., depression, anxiety), and respiratory conditions (e.g., sleep apnea, COVID-19). Early detection enables preventive care and timely interventions, which can lead to better patient outcomes and reduced healthcare costs.

Vocalis Health uses AI-powered voice analysis to detect signs of Parkinson's disease by analyzing subtle changes in speech patterns. The opportunity lies in scaling such technologies for widespread use in remote and at-risk populations, enabling earlier intervention and personalized treatment plans. Similarly, apps such as Sonde Health are leveraging vocal biomarkers to monitor emotional distress, which can indicate early signs of mental health conditions like depression and anxiety. This could lead to proactive interventions and the avoidance of chronic mental health conditions.

Some of the other factors creating an opportunity for market growth include:

Note: All of the above factors will be evaluated in detail in the report.

Market Trends:

The integration of AI and ML into voice/vocal biomarker technologies marks a significant leap forward in the diagnostic and monitoring capabilities of healthcare. These technologies not only provide non-invasive, real-time, and personalized healthcare solutions but also open up new avenues for early disease detection, remote monitoring, and predictive analytics. While challenges around data privacy and clinical validation remain, the potential for AI and ML to revolutionize healthcare through vocal biomarkers is immense, offering substantial benefits in the diagnosis and management of a wide array of health conditions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in voice/vocal biomarker, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses in Voice/Vocal Biomarker and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines specific to Voice/Vocal Biomarker, ensuring organizations stay compliant and accelerate market entry for new voice/vocal biomarker

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

Primary Research:

The primary sources involve industry experts in Voice/Vocal Biomarker, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

Secondary Research

Open Sources

The key data points taken from the secondary sources include:

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

The voice/vocal biomarker market encompasses a wide array of technologies designed to analyze and interpret voice data for various applications, from healthcare diagnostics to emotional intelligence in customer service. As technological advancements in AI and machine learning continue, the voice/vocal biomarker market is set to grow rapidly, impacting industries like healthcare, security, automotive, customer service, and telecommunications. With a growing focus on non-invasive diagnostics, personalized services, and enhanced security, vocal biomarker technologies are becoming a critical part of many sectors, with a particularly strong future in healthcare and voice authentication.

Some prominent names established in the voice/vocal biomarker market are:

Table of Contents

Executive Summary

Scope and Definition

1 Global Voice/Vocal Biomarker Market: Industry Outlook

2 Platform Type

3 Application Type

4 Indication

5 End User

6 Region

7 Competitive Landscape and Company Profiles

8 Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â